Synaptogenix

About:

Synaptogenix is a clinical-stage biopharmaceutical company that develops novel therapies for neurodegenerative diseases.

Website: https://www.synaptogen.com

Twitter/X: synaptogenix

Top Investors: Bantam Group

Description:

Synaptogenix is a clinical-stage biotech company leveraging Bryostatin-1 and its analogs to discover and develop targeted therapeutics for neurodegenerative diseases and developmental disorders. The company has targeted Bryostatin-1 due to its high potential and multi-modal efficacy: through protein kinase C (PKCϵ) activation, Bryostatin-1 stimulates synaptic growth factors, amyloid-β degrading enzymes, as well as prevents Tau transformation into neurofibrillary tangles.

Total Funding Amount:

$68.4M

Headquarters Location:

New York, New York, United States

Founded Date:

2012-01-01

Founders:

Daniel Alkon

Number of Employees:

1-10

Last Funding Date:

2024-09-11

IPO Status:

Public

Industries:

© 2025 bioDAO.ai